MedTrace Logo

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

NCT04715217 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-12-29

No results posted yet for this study

Summary

Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-CD22 CAR-T cells for the treatment of B cell lymphoma.

Conditions

  • Lymphoma, B-Cell

Interventions

BIOLOGICAL

CD19-CD22 CAR-T cells

A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .

Sponsors & Collaborators

  • Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

    collaborator INDUSTRY

  • Shanxi Province Cancer Hospital

    lead OTHER

Principal Investigators

  • Liping Su, M.D. · Hematology Department of ShanXi Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
6 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2024-10-31
Completion
2025-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04715217 on ClinicalTrials.gov